Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Heaven Robbins

Nurse Practitioner, Family New Albany, MS Nurse Practitioner

NPI 1689185464 CMS profile 10619300

216 Oxford Rd, New Albany, MS 38652

Open in the dashboard

General payments

$9,263

695 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Heaven Robbins of New Albany, MS is reported in the CMS Open Payments database as having received $9,263 across 695 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,497 95
2024 General $1,600 131
2023 General $2,189 156
2022 General $2,158 173
2021 General $1,819 140

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heaven Robbins
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Heaven Robbins were reported at $1,497. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Heaven Robbins Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,819 $124 $35–$379 $132
2022 $2,158 $141 $44–$430 $149
2023 $2,189 $154 $49–$476 $160
2024 $1,600 $165 $51–$504 $164
2025 $1,497 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,522 167 payments
  2. GlaxoSmithKline, LLC. $1,032 87 payments
  3. AstraZeneca Pharmaceuticals LP $761 35 payments
  4. Pfizer Inc. $664 50 payments
  5. Lilly USA, LLC $527 45 payments
  6. ITI, Inc. $438 29 payments
  7. Novo Nordisk Inc $412 33 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $343 17 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $331 27 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $260 27 payments
  11. Other $2,973 178 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,263 695 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $925 71 payments
  2. NURTEC ODT Pain $611 46 payments
  3. UBRELVY $489 48 payments
  4. QULIPTA $459 47 payments
  5. VRAYLAR $397 49 payments
  6. Ozempic $395 32 payments
  7. RYBELSUS $379 31 payments
  8. BREZTRI $374 16 payments
  9. NURTEC ODT Primary Care $373 30 payments
  10. MOUNJARO $347 24 payments
  11. Other $6,168 448 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 102 drugs

Part D claims

4,394

Median for Nurse Practitioner: 389

Drug cost

$242,889

Median for Nurse Practitioner: $21,885

Branded share of claims

18.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 65 $48,746
Ozempic Semaglutide Brand 48 $46,409
Jardiance Empagliflozin Brand 31 $23,041
Linzess Linaclotide Brand 18 $16,675
Eliquis Apixaban Brand 23 $14,220
Glyxambi Empagliflozin/Linagliptin Brand 15 $12,790
Rybelsus Semaglutide Brand 11 $10,745
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 15 $9,503
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 12 $7,670
Januvia Sitagliptin Phosphate Brand 13 $7,301

The 10 drugs with the highest cost, of 102 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$31,612

Of which drugs: $582

Medicare patients

240

Average age 74

Services billed

2,508

149 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 43%
Ischemic heart disease 31%
Atrial fibrillation 25%
COPD 21%
Chronic kidney disease 18%
Depression 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ceftriaxone sodium, per 250 mg J0696 Office 86 386 $118
Injection, ketorolac tromethamine, per 15 mg J1885 Office 24 105 $49
Injection, methylprednisolone acetate, 1 mg J1010 Office 40 417 $40
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 63 422 $29

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 37 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
  • PFIZER INC. $206
$206 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $135
$135 — —
VRAYLAR
  • AbbVie, Inc. $117
$117 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $97
$97 15 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $90
$90 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 37 with Patron

Records

695 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record